| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:Anti-ERBB2
Purity:Ab1, Prestige Antibody
|
|
| | ANTI-ERBB2 Basic information |
| Product Name: | ANTI-ERBB2 | | Synonyms: | ANTI-HUMAN EPIDERMAL GROWTH FACTOR;ANTI-HUMAN EPIDERMAL GROWTH FACTOR (AB-4), HUMAN;ANTI-HUMAN EPIDERMAL GROWTH FACTOR (AB-6), HUMAN;ANTI-HUMAN EPIDERMAL GROWTH FACTOR (AB-6) MOUSE MAB;ANTI-HUMAN EPIDERMAL GROWTH FACTOR (AB-7), HUMAN;ANTI-ERBB2;ANTI-ERBB2 (AB-4), HUMAN;ANTI-C-ERBB2/C-NEU (AB-1), HUMAN | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![ANTI-ERBB2 Structure]() |
| | ANTI-ERBB2 Chemical Properties |
| storage temp. | -20°C | | form | buffered aqueous solution |
| | ANTI-ERBB2 Usage And Synthesis |
| Uses | Monoclonal Anti-c-erbB-2 antibody produced in mouse has been used in :
- enzyme linked immunosorbent assay (ELISA)
- immunoprecipitation
- immunohistochemistry
- studies on receptor internalization, phosphorylation, ligand binding and tumor growth inhibition
| | General Description | Monoclonal Anti-c-erbB-2 (HER-2, Neu) (mouse IgG1 isotype) is derived from the (human epidermal growth factor receptor 2) HER2-96 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a BALB/c mouse immunized with a purified extracellular domain of human erbB-2, from transfected cells. The human erbB-2 oncogen (also known as HER2, HER-2 or neu) encodes a transmembrane growth factor orphan receptor with a M.W. of 185 kDa (p185). The complete protein consists of an internal cytoplasmic structure with tyrosine kinase activity, a short hydrophobic transmembrane section and an extracellular ligand-binding domain (ECD). | | Biochem/physiol Actions | Erb-b2 receptor tyrosine kinase 2 (ErbB-2) has a pivotal role in signal transduction, where it can stimulate the signal even in the absence of ligand by forming heterodimers with erbB-1/EGF-R, erbB-3, and erbB-4 and hence can modifies ligand affinity. Thus, erbB-2 alters the intracellular responses elicited by EGF and NDF. This control is due to the fact that erbB-2, when in complex with another erbB family receptor, decelerates the rate of ligand dissociation. Therefore, erbB-2 may act as a signalling subunit for other receptors rather than a true growth factor receptor. Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of certain human adenocarcinomas, the encoded protein is an attractive target for immunotherapy. Indeed, antibodies to erbB-2 were found to block the crosstalk with growth factor receptors. In addition, receptor overexpression is considered a predictor of poor survival and short time of relapse. |
| | ANTI-ERBB2 Preparation Products And Raw materials |
|